253 related articles for article (PubMed ID: 27062695)
1. CD90 a potential cancer stem cell marker and a therapeutic target.
Shaikh MV; Kala M; Nivsarkar M
Cancer Biomark; 2016; 16(3):301-7. PubMed ID: 27062695
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
4. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines.
Shu X; Liu H; Pan Y; Sun L; Yu L; Sun L; Yang Z; Ran Y
Mol Cell Biochem; 2019 Sep; 459(1-2):35-47. PubMed ID: 31073886
[TBL] [Abstract][Full Text] [Related]
5. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W
Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843
[TBL] [Abstract][Full Text] [Related]
6. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines.
Yan X; Luo H; Zhou X; Zhu B; Wang Y; Bian X
Oncol Rep; 2013 Dec; 30(6):2733-40. PubMed ID: 24101104
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin.
Chen WC; Hsu HP; Li CY; Yang YJ; Hung YH; Cho CY; Wang CY; Weng TY; Lai MD
Int J Oncol; 2016 Nov; 49(5):1881-1889. PubMed ID: 27633757
[TBL] [Abstract][Full Text] [Related]
8. CD26 a cancer stem cell marker and therapeutic target.
Davies S; Beckenkamp A; Buffon A
Biomed Pharmacother; 2015 Apr; 71():135-8. PubMed ID: 25960228
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
10. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines.
Shimamura M; Nagayama Y; Matsuse M; Yamashita S; Mitsutake N
Endocr J; 2014; 61(5):481-90. PubMed ID: 24531915
[TBL] [Abstract][Full Text] [Related]
11. Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.
Skowron MA; Niegisch G; Fritz G; Arent T; van Roermund JG; Romano A; Albers P; Schulz WA; Hoffmann MJ
J Exp Clin Cancer Res; 2015 Nov; 34():144. PubMed ID: 26606927
[TBL] [Abstract][Full Text] [Related]
12. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma.
Luo J; Wang P; Wang R; Wang J; Liu M; Xiong S; Li Y; Cheng B
Oncotarget; 2016 Feb; 7(8):9525-37. PubMed ID: 26848615
[TBL] [Abstract][Full Text] [Related]
13. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
14. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.
Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H
J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids.
Oktem G; Sercan O; Guven U; Uslu R; Uysal A; Goksel G; Ayla S; Bilir A
Oncol Rep; 2014 Aug; 32(2):641-9. PubMed ID: 24927163
[TBL] [Abstract][Full Text] [Related]
16. Surface markers of hepatocellular cancer stem cells and their clinical potential.
Feng D; Wang N; Hu J; Li W
Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
[TBL] [Abstract][Full Text] [Related]
17. Significance of CD90+ cancer stem cells in human liver cancer.
Yang ZF; Ho DW; Ng MN; Lau CK; Yu WC; Ngai P; Chu PW; Lam CT; Poon RT; Fan ST
Cancer Cell; 2008 Feb; 13(2):153-66. PubMed ID: 18242515
[TBL] [Abstract][Full Text] [Related]
18. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.
Zhu L; Zhang W; Wang J; Liu R
Tumour Biol; 2015 Jul; 36(7):5353-60. PubMed ID: 25672610
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines.
Lobba AR; Forni MF; Carreira AC; Sogayar MC
Cytometry A; 2012 Dec; 81(12):1084-91. PubMed ID: 23090904
[TBL] [Abstract][Full Text] [Related]
20. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
